Cargando…

Integrated analysis of NET‐DNA receptor CCDC25 in malignant tumors: Pan‐cancer analysis

BACKGROUND: Previously, it was reported that the coiled‐coil domain containing 25 (CCDC25) plays a role in the formation of neutrophil extracellular traps (NETs). This study systematically analyzed the expression profiles of CCDC25 in 30 different types of cancer and one type of blood cancer, acute...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Xianlin, Yin, Xinhai, Song, Jukun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10568976/
https://www.ncbi.nlm.nih.gov/pubmed/37841944
http://dx.doi.org/10.1002/hsr2.1621
_version_ 1785119468691652608
author Cheng, Xianlin
Yin, Xinhai
Song, Jukun
author_facet Cheng, Xianlin
Yin, Xinhai
Song, Jukun
author_sort Cheng, Xianlin
collection PubMed
description BACKGROUND: Previously, it was reported that the coiled‐coil domain containing 25 (CCDC25) plays a role in the formation of neutrophil extracellular traps (NETs). This study systematically analyzed the expression profiles of CCDC25 in 30 different types of cancer and one type of blood cancer, acute myeloid leukemia. METHODS: The GTEx and CCLE databases were used to evaluate the distribution of CCDC25 expression in both normal tissue and cancer cell lines. A comparison was performed between normal tissue and tumor tissue to analyze the differential expression of CCDC25. We assessed the impact of CCDC25 on the clinical outlook in the TCGA pan‐cancer data set by analyzing the Kaplan–Meier survival plot and conducting COX regression analysis. Moreover, the association between the expression levels of CCDC25 and the tumor microenvironment in multiple cancers was conducted. Additionally, the investigation also examined the link between CCDC25 and immune neoantigen, tumor mutational burden, microsatellite instability, mismatch repair genes (MMRs), HLA‐related genes, and DNA methyltransferase (DNMT). RESULTS: CCDC25 was expressed in nearly all of the 31 normal tissues while exhibiting a moderate to low level of expression in cancer cell lines. While abnormal expression was detected in the majority of malignancies, there was no link found between elevated CCDC25 levels and overall survival, disease‐free survival, recurrence‐free survival, and disease‐free interval in the TCGA comprehensive cancer data set. Nevertheless, the expression of CCDC25 exhibited a notable link with the infiltration levels of activated CD4 memory T cells, quiescent mast cells, dendritic cells in an activated state, T cells that assist in follicle development, M2 macrophages, and neutrophils in various tumors. CONCLUSIONS: In most cancers, the results indicate that there is no link between CCDC25 and prognosis. However, CCDC25 can be targeted for therapeutic purposes concerning metastasis and immune infiltration.
format Online
Article
Text
id pubmed-10568976
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-105689762023-10-13 Integrated analysis of NET‐DNA receptor CCDC25 in malignant tumors: Pan‐cancer analysis Cheng, Xianlin Yin, Xinhai Song, Jukun Health Sci Rep Original Research BACKGROUND: Previously, it was reported that the coiled‐coil domain containing 25 (CCDC25) plays a role in the formation of neutrophil extracellular traps (NETs). This study systematically analyzed the expression profiles of CCDC25 in 30 different types of cancer and one type of blood cancer, acute myeloid leukemia. METHODS: The GTEx and CCLE databases were used to evaluate the distribution of CCDC25 expression in both normal tissue and cancer cell lines. A comparison was performed between normal tissue and tumor tissue to analyze the differential expression of CCDC25. We assessed the impact of CCDC25 on the clinical outlook in the TCGA pan‐cancer data set by analyzing the Kaplan–Meier survival plot and conducting COX regression analysis. Moreover, the association between the expression levels of CCDC25 and the tumor microenvironment in multiple cancers was conducted. Additionally, the investigation also examined the link between CCDC25 and immune neoantigen, tumor mutational burden, microsatellite instability, mismatch repair genes (MMRs), HLA‐related genes, and DNA methyltransferase (DNMT). RESULTS: CCDC25 was expressed in nearly all of the 31 normal tissues while exhibiting a moderate to low level of expression in cancer cell lines. While abnormal expression was detected in the majority of malignancies, there was no link found between elevated CCDC25 levels and overall survival, disease‐free survival, recurrence‐free survival, and disease‐free interval in the TCGA comprehensive cancer data set. Nevertheless, the expression of CCDC25 exhibited a notable link with the infiltration levels of activated CD4 memory T cells, quiescent mast cells, dendritic cells in an activated state, T cells that assist in follicle development, M2 macrophages, and neutrophils in various tumors. CONCLUSIONS: In most cancers, the results indicate that there is no link between CCDC25 and prognosis. However, CCDC25 can be targeted for therapeutic purposes concerning metastasis and immune infiltration. John Wiley and Sons Inc. 2023-10-12 /pmc/articles/PMC10568976/ /pubmed/37841944 http://dx.doi.org/10.1002/hsr2.1621 Text en © 2023 The Authors. Health Science Reports published by Wiley Periodicals LLC. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Research
Cheng, Xianlin
Yin, Xinhai
Song, Jukun
Integrated analysis of NET‐DNA receptor CCDC25 in malignant tumors: Pan‐cancer analysis
title Integrated analysis of NET‐DNA receptor CCDC25 in malignant tumors: Pan‐cancer analysis
title_full Integrated analysis of NET‐DNA receptor CCDC25 in malignant tumors: Pan‐cancer analysis
title_fullStr Integrated analysis of NET‐DNA receptor CCDC25 in malignant tumors: Pan‐cancer analysis
title_full_unstemmed Integrated analysis of NET‐DNA receptor CCDC25 in malignant tumors: Pan‐cancer analysis
title_short Integrated analysis of NET‐DNA receptor CCDC25 in malignant tumors: Pan‐cancer analysis
title_sort integrated analysis of net‐dna receptor ccdc25 in malignant tumors: pan‐cancer analysis
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10568976/
https://www.ncbi.nlm.nih.gov/pubmed/37841944
http://dx.doi.org/10.1002/hsr2.1621
work_keys_str_mv AT chengxianlin integratedanalysisofnetdnareceptorccdc25inmalignanttumorspancanceranalysis
AT yinxinhai integratedanalysisofnetdnareceptorccdc25inmalignanttumorspancanceranalysis
AT songjukun integratedanalysisofnetdnareceptorccdc25inmalignanttumorspancanceranalysis